Redirecting to https://news.bms.com/news/corporate-financial/2025/U-S--Food-and-Drug-Administration-Approves-Opdivo-nivolumab-plus-Yervoy-ipilimumab-as-a-First-Line-Treatment-for-Unresectable-or-Metastatic-Hepatocellular-Carcinoma/default.aspx...

Click here if your browser doesn't automatically take you to this page.